Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 712 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

NIAID Centralized Sequencing Protocol

NCT03206099
View directory record Official record
Conditions
Atopy, Primary Immunodeficiency, Autoimmunity, Autoinflammation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 100 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2042
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03989349
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Placebo, Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)

NCT02564055
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Fort Smith, Arkansas • Fresno, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis

NCT00232011
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream 1%
Drug
Lead sponsor
Novartis
Industry
Eligibility
16 Years to 65 Years
Enrollment
160 participants
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Dec 17, 2007 · Synced Oct 30, 2026, 5:45 PM EDT
Recruiting No phase listed Observational

Registry for Systemic Eczema Treatments

NCT06136767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 26 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 30, 2026, 5:45 PM EDT
Recruiting Phase 2 Interventional

Cardamom and Topical Roseomonas in Atopic Dermatitis

NCT06096857
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Roseomonas mucosa (RSM2015) and Cardamom seeds, Placebo (sucrose)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)

NCT00076375
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Nanocrystalline silver cream (NPI)
Drug
Lead sponsor
Nucryst Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Huntsville, Alabama • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema

NCT02691507
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
EpiCeram Skin Barrier Emulsion, Experimental Product 1% Colloidal Oatmeal Balm
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

A Study of LY3471851 in Participants With Eczema

NCT04081350
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
North Little Rock, Arkansas • Encinitas, California • Fremont, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 30, 2026, 5:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Sodium in the Skin and Atopic Dermatitis

NCT06998446
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

NCT04250337
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, Topical Corticosteroid
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
43
States / cities
Scottsdale, Arizona • Anaheim, California • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 4 Interventional

Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects

NCT00139581
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Apr 23, 2008 · Synced Oct 30, 2026, 5:45 PM EDT
Withdrawn Not applicable Interventional

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

NCT01695707
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pioglitazone, Placebo (for pioglitazone)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 30, 2026, 5:45 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis

NCT00465699
View directory record Official record
Conditions
Eczema
Interventions
Topical B12 0.07%
Drug
Lead sponsor
Spartanburg Regional Healthcare System
Other
Eligibility
6 Months to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2007 · Synced Oct 30, 2026, 5:45 PM EDT
Completed No phase listed Observational

Scratch and Sleep Quantification in Atopic Dermatitis

NCT03490877
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Sleep Disturbance
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

NCT03575871
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

NCT03747575
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MSTT1041A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 30, 2026, 5:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

ADRN Barrier/Immunoprofiling Exploratory Pilot Study

NCT02115399
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Non-atopic Healthy Controls
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Denver, Colorado • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

NCT02210780
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 30, 2026, 5:45 PM EDT
Completed No phase listed Observational

A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists

NCT02916888
View directory record Official record
Conditions
Eczema, Dermatitis, Dermatitis, Atopic, Genetic Disease, Inborn, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases, Skin Diseases, Skin Diseases, Eczematous, Skin Diseases, Genetic
Interventions
Care provided by general pediatrician, Care provided by pediatric dermatologist
Other
Lead sponsor
Yale University
Other
Eligibility
Up to 7 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 30, 2026, 5:45 PM EDT
Completed No phase listed Observational

A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)

NCT05235724
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Montgomery, Alabama • Hialeah, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 30, 2026, 5:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology

NCT00696397
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 30, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06130566
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Scottsdale, Arizona • Fountain Valley, California • Fremont, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 5:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

NCT05721937
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 30, 2026, 5:45 PM EDT